ArticleLeukemia research reports2019

Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features.

Xiaochuan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.